AR

Aimee Raleigh

Principal at Atlas Venture

Boston, Massachusetts

Invests in

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Principal

    2023

  • Senior Associate

    2022 - 2023

  • Associate

    2020 - 2022

2018 - 2020

  • Life Sciences Consultant

    2020 - 2020

  • Senior Life Sciences Specialist

    2019 - 2020

    • 15+ engagements across therapeutics and tools / diagnostics with a focus on growth strategy and M&A, including both buy- and sell-side diligences • Present regularly to C-suite executives and manage teams of 1 – 3 • Serve as Head of the Los Angeles office Women’s Network and member of Community Impact Committee Selected transactions include: - Forecast revenue and total addressable market for a global electron microscopy camera supplier to inform a ~$500M potential acquisition, including growth drivers and sensitivity analysis - Evaluated opportunity size and indication expansion strategy for a commercialized bladder cancer Tx - Forecast market size and company revenue for a bioprocessing manufacturer to inform a ~$50M LBO, including market growth, competitor landscape, and customer evaluation - Advised on $5B partnership expansion for a large global biotech (developed revenue forecasts for key pipeline assets and analyzed peak sales scenarios and sensitivities to price and order of market entry) - Evaluated market opportunity, product revenue potential, technical differentiators, competitive landscape, and acquisition deal term comparables for a preclinical CAR-T asset - Forecast total U.S. hospice market and revenue for a national for-profit player, including analysis of key growth drivers and competitive landscape - Supported diligence screen on 100+ late-phase oncology assets based on portfolio fit, clinical feasibility, and peak revenue opportunity

  • Life Sciences Specialist

    2018 - 2019

  • Graduate Researcher

    2013 - 2018

    - Accepted into Gordon Graduate Scholars Program Spring 2015 - Awarded UCSD Frontiers of Innovation Scholarship (FISP) in January 2015 - Awarded Translational Musculoskeletal Research training grant (T32) in Fall 2014 - Coordinated animal study to evaluate the effect of post-traumatic osteoarthritis on key metrics of joint health; directed a team of 5 undergraduates and staff scientists (held weekly progress meetings, coordinated experiments, wrote reports, and summarized findings); project resulted in 2 pending first author presentations and 3 global conference posters and oral presentations TA for the following classes: - BENG 186A (Principals of Biomaterials Design, Undergraduate Level), - BENG 277 (Tissue Engineering Laboratory, Graduate Level) - BENG 241A (Tissue Engineering, Graduate Level)

2012 - 2014

  • Co-Founder

    2012 - 2014

    LuxSano is a company founded on the innovative combination of Ultraviolet C light and pulsatile lavage. We have received funding from the NCIIA E-Team Program and made it to the top 10 finalist round of the Duke StartUp Challenge.

  • Innovation Associate

    2013 - 2013

    Helped to manage and grow portfolio of medical device patents; responded to USPTO Office Actions to improve IP coverage.

2012 - 2013

  • Undergraduate Researcher in the Reichert Lab

    2012 - 2013

    Monitored B lymphocyte migration on chemokine gradients, developed tracking protocols in Imaris

2012 - 2012

  • Molecular Separations Intern

    2012 - 2012

    Developed testing procedures to assess efficiency of both IEX and HILIC chromatography media. Used van Deemter parameters and H-U curves to determine standards of performance.

2011 - 2011

  • LC/MS Intern

    2011 - 2011

    Used Biacore to model protein-protein binding between various glycoforms and lectins.

  • Intern

    2010 - 2010

    Worked on patent development for biomedical devices and assisted in finance management.

2009 - 2009

  • Intern

    2009 - 2009

    Served as a Quality Assurance tester for new software